A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5759-5768

  Kong, Ling Yuan ^a   Abou Ghazal, Mohamed K ^a   Wei, Jun ^a   Chakraborty, Arup ^a   Sun, Wei ^a   Qiao, Wei ^a   Fuller, Gregory N ^a   Fokt, Izabela ^a   Grimm, Elizabeth A ^a   Schmittling, Robert J ^b   Archer Jr , Gary E ^b   Sampson, John H ^b   Priebe, Waldemar ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; JANUS KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; W 1066; WP 1066; CYTOKINE; PYRIDINE DERIVATIVE; STAT3 PROTEIN, MOUSE; TYRPHOSTIN; WP1066;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IC 50; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL MELANOMA; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOKINES; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TYRPHOSTINS;

EID: 53249094201     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0377     Document Type: Article

References (50)

1. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
2. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007;13: 1362-6.
3. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23: 3550-60.
4. Lo HW, Hsu SC, Ali-Seyed M, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005;7:575-89.
5. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-94.
6. Mizoguchi M, Betensky RA, BatchelorTT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-8.
7. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-8.
8. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 2006;54:25-33.
9. Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67:11291-9.
10. Guha S, Chakraborty A, Szymanski S, et al. WP1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. 98th American Association of Cancer Research Annual Meeting, Los Angeles, CA, 2007.
11. Chakraborty A, Guha S, Helgason T, et al. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. 98th American Association of Cancer Research Annual Meeting, Los Angeles, CA, 2007.
12. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2006;26:2435-44.
13. Kupferman ME, Zhou G, Zhao M, et al. A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. 97th American Association of Cancer Research Annual Meeting, Washington, DC, 2006.
14. Kong L-Y, Kapuria V, Bartholomeusz G, Priebe W, Talpaz M, Donato N. Antitumor activity and mechanism of action of a novel Stat3 inhibitor, WP1066, against human B-cell non-Hodgkin's lymphoma and multiple myeloma. Blood. Vol. 106, 2005;429A, 1489 Part1.
15. Kong L-Y, Talpaz M, Priebe W, et al. Novel tyrphostin analogues inhibit Stat3 activation and induce apoptosis in multiple hematological malignancies. The 45th Annual Meeting of the American Society of Hematology San Diego, CA, 2003.
16. Donato NJ, Wu J, Kong L-Y, Meng F, Priebe W, Talpaz M. Targeting BCR-ABL and its downstream signaling cascade as therapy for chronic myelogenous leukemia. The 46th Annual Meeting of the American Society of Hematology, San Diego, CA, 2004.
17. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
18. Kortylewski M, Yu H. Stat3 as a potential target for cancer immunotherapy. J Immunother (1997) 2007; 30:131-9.
19. Hussain SF, Kong L-Y, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-6.
20. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
21. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9:4247-54.
22. Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, StroberW. Current protocols in immunology. New York: Green & Wiley Interscience; 1994.
23. Heimberger AB, Sun W. Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neurooncol. E-pub 2007.
24. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncol 2006;8:261-79.
25. Kaplan EL. Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
27. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary (NC): SAS Institute Inc.; 1996.
28. Yang XO, Panopoulos AD. Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helperTcells. J Biol Chem 2007;282:9358-63.
29. Foley JF. STAT3 regulates the generation of Th17 cells. Sci STKE 2007;2007:tw113.
30. Bettelli E, Oukka M, KuchrooVK.T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.
31. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21.
32. Kinjyo I, Inoue H, Hamano S, et al. Loss of SOCS3 inT helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-fit J Exp Med 2006;203:1021-31.
33. Zom E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
34. Yoshimura A, NakaT, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454-65.
35. Starr R. WillsonTA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387:917-21.
36. Qin H, Roberts KL, Niyongere SA, Cong Y, Elson CO, Benveniste EN. Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol 2007;179:5966-76.
37. Pillemer BB, Xu H, OrissTB, Qi Z, Ray A. Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. Eur J Immunol 2007;37:2082-9.
38. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic ami-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatoryTcells. Clin Cancer Res 2006;12:4294-305.
39. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13:2158-67.
40. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatoryTceHs and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
41. Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002;50:158-64; discussion 64-6.
42. Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001;84:72-9.
43. ChanaJS, Graver R, Tulley P, et al The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma. Br J Plast Surg 2002;55:623-7.
44. Mrowietz U, Schwenk U, Maune S, et aL The chemokine RANTES is secreted by human melanoma Cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999;79:1025-31.
45. Wang T. Niu G. Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
46. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66: 3294-302.
47. El Andaloussi A. Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007;83:145-52.
48. Jordan JT, Sun WH, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-31.
49. Bao JJ, Fokt I, Szymanski S, Priebe W. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clin Cancer Res 2005;11:9026-7S.
50. Samanta A, Kantaijian H, Priebe W, Arlinghaus R. Cross talk between Jak2 and Lyn in Bcr-Abl signaling pathway in cells from Imatinib-sensitive and resistant chronic myelogenous leukemia (CML). 98th American Association of Cancer Research Annual Meeting. Los Angeles, CA, 2007.